News
DNLI
20.52
-1.20%
-0.25
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
NASDAQ · 1d ago
Weekly Report: what happened at DNLI last week (0318-0322)?
Weekly Report · 4d ago
Denali Therapeutics files to sell 29.29M shares of common stock for holders
Seeking Alpha · 6d ago
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Denali Therapeutics Inc. Share price has rebounded 25% in the last month but is still down 5.7%. The company has a modest price-to-sales ratio of 9x. The company's revenue growth is expected to slump over the next three years. Its P/S ratio is lower than the majority of companies in the biotech industry.
Simply Wall St · 03/21 10:37
Denali Therapeutics (NASDAQ:DNLI investor three-year losses grow to 67% as the stock sheds US$223m this past week
Denali Therapeutics Inc. Share price has risen 18% in the last month, but over the last three years the stock has dropped 67%. The company's revenue has dropped 6.7% per year in the past three years. The company is not currently profitable, and shareholders have lost 14% over the same period. DenaliTherapeutics has lost 7.4% in last week. We look at the company to see if there are any red flags for investors.
Simply Wall St · 03/19 11:49
Weekly Report: what happened at DNLI last week (0311-0315)?
Weekly Report · 03/18 09:23
Weekly Report: what happened at DNLI last week (0304-0308)?
Weekly Report · 03/11 09:23
Why Biotech Stocks May Be Ready For A Recovery
Biotech stocks have struggled in recent quarters as high interest rates take a toll on the capital-intensive sector. Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with MoneyTalk's Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a recovery.
Seeking Alpha · 03/09 08:59
Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Seeking Alpha · 03/07 03:05
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Analysts Offer Insights on Healthcare Companies: Straumann Holding AG (Six Swiss: CH:STMN), Denali Therapeutics (DNLI) and arGEN X (GB:0QW0)
Straumann Holding AG, Denali Therapeutics and arGEN X have 3 analysts with bullish sentiments on the Healthcare sector. 3 analysts have maintained Buy ratings on the 3 stocks. The 3 companies are expected to make moves following their insider activities. Straumann holding AG and Denali and argen X are both in the healthcare sector.
TipRanks · 03/05 09:06
Weekly Report: what happened at DNLI last week (0226-0301)?
Weekly Report · 03/04 09:23
Denali Therapeutics (DNLI) Gets a Buy from Oppenheimer
TipRanks · 03/01 12:47
Strong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite Dilution
TipRanks · 03/01 06:00
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
Shares of Denali Therapeutics are trading up 2.62% over the last 24 hours. Goldman Sachs has lower its price target from $73.00 to $50.00. The company is engaged in developing and discovering therapeutics to defeat neurodegeneration disease.
Benzinga · 02/29 17:00
Denali Therapeutics Is Maintained at Buy by Goldman Sachs
Dow Jones · 02/29 15:07
Denali Therapeutics Price Target Cut to $50.00/Share From $73.00 by Goldman Sachs
Dow Jones · 02/29 15:07
Goldman Sachs Maintains Buy on Denali Therapeutics, Lowers Price Target to $50
Benzinga · 02/29 14:57
4 Analysts Assess Denali Therapeutics: What You Need To Know
Denali Therapeutics is a biotechnology company developing drugs to defeat neurodegeneration disease. The company has an average price target of $65.75 for the next 12 months. In the last three months, 4 analysts have published ratings on DenaliTherapeutics. The biotechnology firm has a strong ROE and exceeds industry averages.
Benzinga · 02/28 19:00
Denali Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/28 17:37
More
Webull provides a variety of real-time DNLI stock news. You can receive the latest news about Denali Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).